ADAMTS13

ADAMTS13

ADAMTS13 is a zinc-containing metalloprotease enzyme that plays a crucial role in the regulation of blood coagulation. It is part of the ADAMTS (A Disintegrin And Metalloproteinase with Thrombospondin Motifs) family of proteins, which are involved in various biological processes, including coagulation, inflammation, and tissue remodeling.

Structure and Function

ADAMTS13 is primarily synthesized in the liver and circulates in the plasma. It is responsible for cleaving von Willebrand factor (vWF), a large multimeric protein that is essential for platelet adhesion and aggregation at sites of vascular injury. By cleaving vWF, ADAMTS13 regulates its size and activity, preventing excessive platelet aggregation and thrombus formation.

The enzyme specifically cleaves the Tyr1605-Met1606 bond in the A2 domain of vWF. This action reduces the size of vWF multimers, which are otherwise highly thrombogenic. The regulation of vWF by ADAMTS13 is critical for maintaining hemostatic balance.

Clinical Significance

Deficiency or dysfunction of ADAMTS13 is associated with a rare but serious condition known as Thrombotic Thrombocytopenic Purpura (TTP). TTP is characterized by the formation of small blood clots throughout the body, leading to thrombocytopenia, hemolytic anemia, and organ damage. There are two main types of TTP:

• Congenital TTP (Upshaw-Schulman syndrome): Caused by inherited mutations in the ADAMTS13 gene, leading to a severe deficiency of the enzyme.
• Acquired TTP: Often due to the development of autoantibodies against ADAMTS13, inhibiting its activity.

Diagnosis of TTP involves measuring ADAMTS13 activity levels and detecting the presence of inhibitors. Treatment typically includes plasma exchange and immunosuppressive therapy to remove inhibitors and restore enzyme activity.

Genetics

The ADAMTS13 gene is located on chromosome 9q34.2. Mutations in this gene can lead to congenital TTP. The gene encodes a protein of 1427 amino acids, which includes a signal peptide, a propeptide, a metalloprotease domain, a disintegrin-like domain, a thrombospondin type 1 motif, and other domains that contribute to its function and regulation.

Research and Developments

Ongoing research is focused on understanding the detailed mechanisms of ADAMTS13 function and regulation, as well as developing novel therapies for TTP. Recombinant ADAMTS13 and gene therapy are being explored as potential treatments for patients with congenital TTP.

Also see

• Von Willebrand factor
• Thrombotic Thrombocytopenic Purpura
• Coagulation
• Metalloprotease

Resources

Latest articles - ADAMTS13

• Most recent articles
• Ongoing trials

Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on ADAMTS13 for any updates.

‎